LogicBio Therapeutics, Inc. (LOGC) News
Filter LOGC News Items
LOGC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LOGC News From Around the Web
Below are the latest news stories about LOGICBIO THERAPEUTICS INC that investors may wish to consider to help them evaluate LOGC as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Logicbio Therapeutics (LOGC)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clene (CLNN – Research Report) and Logicbio Therapeutics (LOGC – Research Report). Clene (CLNN) In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Clene, with a price target of $16.00. The company's shares closed last Monday at $1.81. According to TipRanks. |
Blue Apron (APRN) Stock Falls 33% on CFO Departure, Stock SaleBlue Apron (APRN) stock is sliding lower on Monday as investors react to its CFO leaving the company and plans for a stock sale. |
GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This WeekInvestors are still interested in short squeeze stocks lately and we've got them covered with the ones to watch this week! |
Why Is LogicBio (LOGC) Stock Up 600% Today?LogicBio (LOGC) stock is seeing massive gains on Monday following news that AstraZeneca (AZN) subsidiary Alexion is acquiring the company. |
AstraZeneca acquires local startup at 660% premiumAstraZeneca Rare Disease, the local division formed when the British pharma giant acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium. AstraZeneca plc (Nasdaq: AZN) is buying LogicBio Therapeutics Inc. (Nasdaq: LOGC) for $2.07 per share, a 660% premium that values the total acquisition at $68 million. Lexington-based LogicBio has been struggling since February, when the U.S. Food and Drug Administration ordered a halt to an early-stage trial testing a drug in pediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats. |
LogicBio's stock skyrockets after buyout bid for a 667% premiumShares of LogicBio Therapeutics Inc. skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company announced an agreement to be acquired by AstraZeneca PLC's Alexion, AstraZeneca Rare Disease in a deal that values LogicBio at about $68.23 million. The stock had closed Friday at a record low of 27 cents, representing a market capitalization for LogicBio of about $8.9 million. Under terms of the buyout deal, Alexi |
Why Are LogicBio Therapeutics Shares Skyrocketing Today?AstraZeneca Plc's (NASDAQ: AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ: LOGC) for $2.07 per share. Both boards have unanimously approved the transaction. Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock. It plans to retain LogicBio employees at their current location. Also Read: LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatri |
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic MedicineWILMINGTON, Del., October 03, 2022--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development. |
The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase LabsConsolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs are part of the Zacks top Analyst Blog . |
5 Big Winners as Dollar Strengthens on Fed Rate HikeA stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation. |